Piramal Life Sciences has commenced phase I trial of a new experimental drug molecule P2202 for diabetes metabolic syndrome in Canada. P2202 is the second compound from Eli Lilly and is part of the collaborative agreement between two companies and is being developed for diabetes metabolic syndrome.
The metabolic syndrome is characterised by a group of metabolic risk factors such as abdominal obesity, blood fat disorders that foster plaque build ups in artery walls, elevated blood pressure, insulin resistance and pro-inflammatory state. People with metabolic syndrome are at increased risk of coronary heart disease, stroke and type 2 diabetes.
P2202 is being developed for the treatment of metabolic disorders. Piramal Life Sciences had submitted the clinical trial application for P2202 to Health Canada, Canada's regulatory authority. This body has approved company's application to initiate phase I study of P2202.
